Supplemental Figure S1: a) NB1 NB3 NB4 NB8 NB15 pPKB(Ser473) PKB(total) GAPDH b) NB1 NB3 Infect. - + - + FOXO3(A3)ER TM ectopic FOXO3 endogenous 1.3 7.8 ratio ectopic/endogenous GAPDH c) Magnification Merge (neg Ctr) Hoechst FOXO3 Merge FOXO3 Merge NB1 NB3
Supplemental Figure S2: a) 60 60 60 24h NB1/Ctr 48h NB1/Ctr 72h NB1/Ctr NB1 NB1/FOXO3 NB1/FOXO3 NB1/FOXO3 50 50 50 40 40 40 % cell death % cell death % cell death 30 30 30 20 20 20 10 10 10 0 0 0 0 nM 25 nM 50 nM 100 nM 250 nM 500 nM 0 nM 25 nM 50 nM 100 nM 250 nM 500 nM 0 nM 25 nM 50 nM 100 nM 250 nM 500 nM 4OHT 4OHT 4OHT 60 60 60 NB3 24h NB3/Ctr 48h NB3/Ctr 72h NB3/Ctr NB3/FOXO3 NB3/FOXO3 NB3/FOXO3 50 50 50 40 40 40 % cell death % cell death % cell death *** *** ** ** 30 30 30 *** ** ** ** ** 20 20 20 10 10 10 0 0 0 0 nM 25 nM 50 nM 100 nM 250 nM 500 nM 0 nM 25 nM 50 nM 100 nM 250 nM 500 nM 0 nM 25 nM 50 nM 100 nM 250 nM 500 nM 4OHT 4OHT 4OHT 60 60 60 24h NB4/Ctr 48h NB4/Ctr 72h NB4/Ctr NB4 NB4/FOXO3 NB4/FOXO3 NB4/FOXO3 50 50 50 40 40 40 % cell death % cell death % cell death 30 30 30 20 20 20 10 10 10 0 0 0 0 nM 25 nM 50 nM 100 nM 250 nM 500 nM 0 nM 25 nM 50 nM 100 nM 250 nM 500 nM 0 nM 25 nM 50 nM 100 nM 250 nM 500 nM 4OHT 4OHT 4OHT 60 60 60 24h NB8/Ctr 48h NB8/Ctr 72h NB8/Ctr NB8 NB8/FOXO3 NB8/FOXO3 NB8/FOXO3 50 50 50 40 40 40 % cell death % cell death % cell death 30 30 30 20 20 20 10 10 10 0 0 0 0 nM 25 nM 50 nM 100 nM 250 nM 500 nM 0 nM 25 nM 50 nM 100 nM 250 nM 500 nM 0 nM 25 nM 50 nM 100 nM 250 nM 500 nM 4OHT 4OHT 4OHT 60 60 60 72h NB15/Ctr 24h NB15/Ctr 48h NB15/Ctr NB15 NB15/FOXO3 NB15/FOXO3 NB15/FOXO3 50 *** 50 50 *** *** *** ### 40 40 40 ** % cell death % cell death % cell death ## *** ** ### *** 30 30 *** 30 ** 20 20 20 10 10 10 0 0 0 0 nM 25 nM 50 nM 100 nM 250 nM 500 nM 0 nM 25 nM 50 nM 100 nM 250 nM 500 nM 0 nM 25 nM 50 nM 100 nM 250 nM 500 nM 4OHT 4OHT 4OHT
b) NB4/FOXO3 NB8/FOXO3 24 h 48 h 72 h 24 h 48 h 72 h 63.0% 63.0% 57.0% 57.0% 52.0% 52.0% 55.1% 55.1% 53.2% 53.2% 60.5% 60.5% - 4OHT - 4OHT 11.7% 11.7% 15.4% 15.4% 14.4% 14.4% 13.9% 13.9% 13.7% 13.7% 12.6% 12.6% 9.7% 9.7% 11.3% 11.3% 12.9% 12.9% 12.5% 12.5% 14.6% 14.6% 8.8% 8.8% 62.6% 62.6% 56.7% 56.7% 57.7% 57.7% 57.8% 57.8% 57.1% 57.1% 59.3% 59.3% + 4OHT + 4OHT 10.6% 10.6% 14.3% 14.3% 13.2% 13.2% 12.9% 12.9% 13.4% 13.4% 12.8% 12.8% 11.2% 11.2% 8.7% 8.7% 11.3% 11.3% 14.1% 14.1% 12.9% 12.9% 8.8% 8.8% NB15/FOXO3 24 h 72 h 48 h 49.7% 49.7% 54.0% 54.0% 51.7% 51.7% 23.2% 23.2% 21.8% 21.8% 26.0% 26.0% - 4OHT 14.3% 14.3% 10.4% 10.4% 12.1% 12.1% 67.6% 67.6% 34.6% 34.6% 61.7% 61.7% + 4OHT 12.5% 12.5% 7.0% 7.0% 6.2% 6.2% 9.9% 9.9% 8.1% 8.1% 13.8% 13.8%
Supplemental Figure S3: 200 NB4/FOXO3 180 NB8/FOXO3 160 BCLXL mRNA expression NB15/FOXO3 (fold over control) 140 120 100 80 *** 60 *** *** *** 40 20 0 0h 3h 6h 9h 140 NB4/FOXO3 NB8/FOXO3 120 BIRC5 mRNA expression NB15/FOXO3 100 (fold over control) 80 ** *** *** 60 40 20 0 0h 3h 6h 9h
Supplemental Figure S4: a) 60 NB4/FOXO3 BIM_02 methylation (PMR %) NB8/FOXO3 50 NB15/FOXO3 40 30 ** 20 * 10 0 untreated 4OHT 5-azadC b) Input IP:FOXO3 IP:IgG NB15 NB4 NB8 NB15 NB4 NB8 NB15 FOXO3 Ac-FOXO3 1.02 0.98 1.43 0.0 % Ac-FOXO3/IP-FOXO3 Tubulin
Supplemental Figure S5: NB1 TP53 (homo sapiens) 393 aa 1 44 102 292 325 356 NB3 TAD TET DNA-binding domain Mutation site codon 72 Pro → Arg (C→G) TP53 wt TP53 NB1 * TP53 NB3 NB4 TP53 NB4 TP53 NB8 TP53 NB15 NB8 NB15
Supplemental Figure S6: 3 NB15 0h Etop NB15 2h Etop * (fold over control) NB15 4h Etop mRNA expression * * 2 * 1 0 BIM NOXA SESN3 5 NB4 0h Etop * NB4 2h Etop NB4 4h Etop 4 (fold over control) mRNA expression ** 3 2 1 0 BIM NOXA SESN3 4 NB8 0h Etop NB8 2h Etop ** NB8 4h Etop (fold over control) mRNA expression 3 *** 2 # # 1 *** * 0 BIM NOXA SESN3
Supplemental Figure S7: NB1/Ctr NB1/FOXO3 control Etop Doxo control Etop Doxo - 4OHT + 4OHT 120 120 without 4OHT without 4OHT with 4OHT with 4OHT 100 100 80 colonies [%] 80 colonies [%] 60 ** 60 * 40 40 ### ## 20 20 0 0 untreated Etop Doxo untreated Etop Doxo NB1/Ctr NB1/FOXO3
Supplemental Figure S8: a) 120 120 100 SESN3 mRNA expression 100 SESN3 mRNA expression (fold over control) (fold over control) 80 *** 80 60 *** 60 40 40 20 20 0 0 NB8/FOXO3-shCtr NB8/FOXO3-shSESN3 NB4/FOXO3-shCtr NB4/FOXO3-shSESN3 b) NB8/FOXO3-shCtr NB8/FOXO3-shSESN3 300 untreated untreated Etop untreated Etop 2h Etop 250 ROS % of untreated Ctr Bright field 200 * 150 100 CM-H 2 XROS 50 0 NB8/FOXO3-shCtr NB8/FOXO3-shSESN3 NB4/FOXO3-shCtr NB4/FOXO3-shSESN3 untreated Etop untreated Etop 300 untreated Bright field 2h Etop 250 ROS % of untreated Ctr 200 * 150 CM-H 2 XROS 100 50 0 NB4/FOXO3-shCtr NB4/FOXO3-shSESN3 c) NB8 shCtr shFOXO3-17 FOXO3 GAPDH 100 44 % FOXO3/GAPDH
Recommend
More recommend